UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

April 20, 2007

OCULUS INNOVATIVE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-33216	68-0423298		
(State or other jurisdiction (Commission		(I.R.S. Employer		
of incorporation)	File Number)	Identification No.)		
1129 N. McDowell Blvd, Petaluma, California		94954		
(Address of principal executive offices)		(Zip Code)		
Registrant's telephone number, including area code:		(707) 782-0792		
	Not Applicable			
Former nam	e or former address, if changed since	last report		
Check the appropriate box below if the Form 8-K fil any of the following provisions:	ing is intended to simultaneously sat	isfy the filing obligation of the registrant under		
 Written communications pursuant to Rule 425 u Soliciting material pursuant to Rule 14a-12 unde Pre-commencement communications pursuant to Pre-commencement communications pursuant to 	er the Exchange Act (17 CFR 240.14 o Rule 14d-2(b) under the Exchange	a-12) Act (17 CFR 240.14d-2(b))		

Top of the Form

Item 5.02 Departure of Directors or	Certain Officers; Elec	ction of Directors;	Appointment o	f Certain Officers	; Compensatory
Arrangements of Certain Officers.					

Effective April 20, 2007, Dr. Jay Edward Birnbaum was elected to serve as an independent director on the Board of Directors of Oculus Innovative Sciences, Inc. Mr. Birnbaum will serve on the Audit Committee of our Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OCULUS INNOVATIVE SCIENCES, INC.

By: /s/ Robert Miller

Name: Robert Miller

Title: Chief Financial Officer

April 24, 2007